Skip to content
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
    • VTX–806 – Cerebrotendinous Xanthomatosis
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet
Menu
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
    • VTX–806 – Cerebrotendinous Xanthomatosis
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Category: Events

Vivet participating to a panel at 2018 Biotech & Money congress

ean-Philippe Combal, Vivet Therapeutics’ CEO

Vivet hosting meetings during JPM 2018 Healthcare Conference

Jean-Philippe Combal, Vivet Therapeutics’ CEO

Vivet attending Jefferies 2017 London Healthcare Conference

Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2017 London Healthcare Conference on…

Vivet will be at BIO Europe in Berlin on November 6-8th

Vivet Therapeutics will be at BIO Europe in Berlin on November 6-8th 2017

Vivet presenting at Gene Therapy for Rare Disorders Europe

Vivet Therapeutics will be presenting at Gene Therapy for Rare Disorders Europe on Oct 31-Nov 2, 2017

Vivet will be at AASLD Liver Meeting 2017

Vivet Therapeutics will be at

Vivet at Mkt Access for Cell & Gene Therapies Congress in London

Vivet Therapeutics will be attending the upcoming

Vivet at 25th anniversary ESGCT meeting in Berlin

Vivet Therapeutics will be at the upcoming European Society of Gene And Cell Therapy (ESGCT) annual meeting in Berlin on Oct. 17-20,…

← Previous
Twitter Linkedin
About us
  • Our DNA
  • Board members
  • Our leadership
  • Partners
  • Our DNA
  • Board members
  • Our leadership
  • Partners
Pipeline
  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1
  • VTX – 806 – Cerebrotendinous Xanthomatosis
Patients & Families
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact

Vivet Therapeutics Cookie Policy